Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 15:2:163.
doi: 10.3389/fonc.2012.00163. eCollection 2012.

Interactions between epigenetics and metabolism in cancers

Affiliations

Interactions between epigenetics and metabolism in cancers

Jihye Yun et al. Front Oncol. .

Abstract

Cancer progression is accompanied by widespread transcriptional changes and metabolic alterations. While it is widely accepted that the origin of cancer can be traced to the mutations that accumulate over time, relatively recent evidence favors a similarly fundamental role for alterations in the epigenome during tumorigenesis. Changes in epigenetics that arise from post-translational modifications of histones and DNA are exploited by cancer cells to upregulate and/or downregulate the expression levels of oncogenes and tumor suppressors, respectively. Although the mechanisms behind these modifications, in particular how they lead to gene silencing and activation, are still being understood, most of the enzymatic machinery of epigenetics require metabolites as substrates or cofactors. As a result, their activities can be influenced by the metabolic state of the cell. The purpose of this review is to give an overview of cancer epigenetics and metabolism and provide examples of where they converge.

Keywords: IDH mutations; NAD metabolism; TCA cycle; Warburg effect; histone modifications; metabolic signaling; α-ketoglutarate and cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Interactions between metabolism and epigenetics. Metabolites that are used as substrates and cofactors for reactions that coordinate epigenetic status (red colors) are centered in this diagram, with the corresponding enzymes that utilize them shown with their chemical reactions. Abbreviation used in this figure: AceCS1, Acetyl-CoA synthetase 1; ACL, ATP-citrate lysase; Ac-CoA, Acetyl-CoA; Acy-protein, Acetylated-protein; Ado, Adenosine; α-KG, α-ketoglutarate; CoA, Co-enzyme; DNMT, DNA methyltransferase; ETC, Electron transport chain; FAD, Flavine adenine dinucleotide; FADH2, Flavin adenine dinucleotide dihydride; GSH, Glutathione; HAT, Histone acetyltransferases; Hcy, Homocystein; HDM, Histone demethylases; 2-HG, 2-hydroxyglutarate; HMT, Histon methyltransferase; IDH1/2, Isocitrate dehydrogenases 1/2; JMDH, JmjC (Jumonji C) domain demethylase; LSD1, Lysine-specific demethylase 1; MAT, Methionine adenosyltransferase; Mut, mutation; NAD+, Nicotinamide adenine dinucleotide; NADH, Nicotinamide adenine dinucleotide hydride; SAH, S-adenosylhomocysteine; SAHH, SAH hydrolase; SAM, S-adenosylmethionine; TCA, Tricarboxylic acid; TET2, Ten-eleven translocation 2.

References

    1. The Cancer Genome Atlas Network. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 10.1038/nature11252 - DOI - PMC - PubMed
    1. Amary M. F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., et al. (2011a). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334–343 10.1002/path.2913 - DOI - PubMed
    1. Amary M. F., Damato S., Halai D., Eskandarpour M., Berisha F., Bonar F., et al. (2011b). Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat. Genet. 43, 1262–1265 10.1038/ng.994 - DOI - PubMed
    1. Anderson R. M., Bitterman K. J., Wood J. G., Medvedik O., Sinclair D. A. (2003). Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423, 181–185 10.1038/nature01578 - DOI - PMC - PubMed
    1. Andersson A. K., Miller D. W., Lynch J. A., Lemoff A. S., Cai Z., Pounds S. B., et al. (2011). IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia 25, 1570–1577 10.1038/leu.2011.133 - DOI - PMC - PubMed